BIOCON | VENUS REMEDIES | BIOCON / VENUS REMEDIES |
|||
---|---|---|---|---|---|
P/E (TTM) | x | 35.5 | -8.1 | - | View Chart |
P/BV | x | 4.5 | 0.5 | 834.3% | View Chart |
Dividend Yield | % | 0.2 | 0.0 | - |
![]() ![]() |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
BIOCON Mar-19 |
VENUS REMEDIES Mar-18 |
BIOCON / VENUS REMEDIES |
5-Yr Chart Click to enlarge
|
||
High | Rs | 707 | 126 | 561.8% | |
Low | Rs | 554 | 61 | 906.4% | |
Sales per share (Unadj.) | Rs | 91.9 | 301.8 | 30.5% | |
Earnings per share (Unadj.) | Rs | 16.7 | -24.9 | -67.2% | |
Cash flow per share (Unadj.) | Rs | 24.2 | 2.5 | 950.0% | |
Dividends per share (Unadj.) | Rs | 1.00 | 0 | - | |
Dividend yield (eoy) | % | 0.2 | 0 | - | |
Book value per share (Unadj.) | Rs | 101.6 | 293.3 | 34.7% | |
Shares outstanding (eoy) | m | 600.00 | 12.34 | 4,862.2% | |
Bonus/Rights/Conversions | - | - | - | ||
Price / Sales ratio | x | 6.9 | 0.3 | 2,214.5% | |
Avg P/E ratio | x | 37.7 | -3.8 | -1,003.7% | |
P/CF ratio (eoy) | x | 26.1 | 36.7 | 71.0% | |
Price / Book Value ratio | x | 6.2 | 0.3 | 1,946.1% | |
Dividend payout | % | 6.0 | 0 | - | |
Avg Mkt Cap | Rs m | 378,330 | 1,154 | 32,790.2% | |
No. of employees | `000 | 6.1 | 0.9 | 662.8% | |
Total wages/salary | Rs m | 11,653 | 393 | 2,964.4% | |
Avg. sales/employee | Rs Th | 8,994.3 | 4,026.1 | 223.4% | |
Avg. wages/employee | Rs Th | 1,900.7 | 425.0 | 447.2% | |
Avg. net profit/employee | Rs Th | 1,635.3 | -331.8 | -492.9% |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 55,144 | 3,724 | 1,480.7% | |
Other income | Rs m | 1,444 | 23 | 6,417.8% | |
Total revenues | Rs m | 56,588 | 3,747 | 1,510.4% | |
Gross profit | Rs m | 15,883 | 395 | 4,023.0% | |
Depreciation | Rs m | 4,478 | 338 | 1,323.7% | |
Interest | Rs m | 709 | 354 | 200.1% | |
Profit before tax | Rs m | 12,140 | -275 | -4,409.7% | |
Minority Interest | Rs m | 9 | 0 | - | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 2,123 | 32 | 6,718.4% | |
Profit after tax | Rs m | 10,026 | -307 | -3,266.9% | |
Gross profit margin | % | 28.8 | 10.6 | 271.7% | |
Effective tax rate | % | 17.5 | -11.5 | -152.4% | |
Net profit margin | % | 18.2 | -8.2 | -220.6% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 48,228 | 2,638 | 1,828.4% | |
Current liabilities | Rs m | 30,376 | 2,305 | 1,318.0% | |
Net working cap to sales | % | 32.4 | 8.9 | 362.0% | |
Current ratio | x | 1.6 | 1.1 | 138.7% | |
Inventory Days | Days | 68 | 135 | 50.4% | |
Debtors Days | Days | 86 | 46 | 184.6% | |
Net fixed assets | Rs m | 64,130 | 4,871 | 1,316.6% | |
Share capital | Rs m | 3,000 | 123 | 2,431.1% | |
"Free" reserves | Rs m | 57,980 | 3,496 | 1,658.6% | |
Net worth | Rs m | 60,980 | 3,619 | 1,684.9% | |
Long term debt | Rs m | 15,766 | 1,374 | 1,147.1% | |
Total assets | Rs m | 121,924 | 7,509 | 1,623.8% | |
Interest coverage | x | 18.1 | 0.2 | 8,127.7% | |
Debt to equity ratio | x | 0.3 | 0.4 | 68.1% | |
Sales to assets ratio | x | 0.5 | 0.5 | 91.2% | |
Return on assets | % | 8.8 | 0.6 | 1,394.7% | |
Return on equity | % | 16.4 | -8.5 | -193.9% | |
Return on capital | % | 16.8 | 1.6 | 1,059.0% | |
Exports to sales | % | 28.1 | 0 | - | |
Imports to sales | % | 18.9 | 13.9 | 136.0% | |
Exports (fob) | Rs m | 15,506 | NA | - | |
Imports (cif) | Rs m | 10,399 | 517 | 2,013.2% | |
Fx inflow | Rs m | 15,506 | 0 | - | |
Fx outflow | Rs m | 10,399 | 517 | 2,013.4% | |
Net fx | Rs m | 5,107 | -517 | -988.8% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 11,546 | 514 | 2,244.6% | |
From Investments | Rs m | -7,138 | -123 | 5,798.5% | |
From Financial Activity | Rs m | -2,417 | -387 | 624.4% | |
Net Cashflow | Rs m | 2,103 | 4 | 50,071.4% |
Indian Promoters | % | 40.4 | 32.9 | 123.0% | |
Foreign collaborators | % | 20.6 | 0.0 | - | |
Indian inst/Mut Fund | % | 8.4 | 0.2 | 4,666.7% | |
FIIs | % | 10.7 | 0.6 | 1,844.8% | |
ADR/GDR | % | 0.0 | 0.0 | - | |
Free float | % | 19.9 | 66.4 | 30.0% | |
Shareholders | 109,995 | 20,121 | 546.7% | ||
Pledged promoter(s) holding | % | 0.0 | 36.4 | 0.1% |
Compare BIOCON With: JUBILANT LIFE SCIENCES DR. DATSONS LABS WOCKHARDT GSK PHARMA PANACEA BIOTECH
Compare BIOCON With: MYLAN (US) ADCOCK INGRAM (S. Africa) ACTAVIS (US) TEVA PHARMA (Israel)
Nifty and Sensex ended the week gaining 0.60% and 0.52% respectively. Bulls started the week roaring but since Wednesday, the momentum seemed to be tiring.
For the quarter ended September 2020, BIOCON has posted a net profit of Rs 2 bn (down 23.9% YoY). Sales on the other hand came in at Rs 17 bn (up 11.0% YoY). Read on for a complete analysis of BIOCON 's quarterly results.
For the quarter ended December 2019, BIOCON has posted a net profit of Rs 2 bn (up 1.2% YoY). Sales on the other hand came in at Rs 17 bn (up 13.5% YoY). Read on for a complete analysis of BIOCON 's quarterly results.
For the quarter ended September 2019, BIOCON has posted a net profit of Rs 3 bn (down 30.5% YoY). Sales on the other hand came in at Rs 16 bn (up 19.0% YoY). Read on for a complete analysis of BIOCON 's quarterly results.
For the quarter ended June 2019, BIOCON has posted a net profit of Rs 1 bn (down 11.5% YoY). Sales on the other hand came in at Rs 5 bn (down 57.2% YoY). Read on for a complete analysis of BIOCON 's quarterly results.
For the quarter ended March 2019, VENUS REMEDIES has posted a net profit of Rs 104 m (down 11.1% YoY). Sales on the other hand came in at Rs 864 m (down 7.3% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.
More Views on NewsMy new guide will show you the huge potential in future proof businesses.
The smallcap rally has enough steam left in it. If you haven't joined yet, it is still not too late.
The charts are telling the bulls to be cautious.
Were you shocked that bullion prices hit lower circuits on Friday on the MCX? Find out why it happened...
Ajit Dayal on the investing strategy for 2021 and beyond.
More